Back to News
Market Impact: 0.25
Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26
Source: Nasdaq
Healthcare & Biotech
Teva presented positive post-hoc data from the Phase 3 SOLARIS trial of TEV-'749 for schizophrenia at the Psych Congress in New Orleans. The update supports the clinical profile of Teva's investigational treatment, although the article did not disclose efficacy figures, safety data, regulatory timing, or commercial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TEVA0.72
More News
- Blackstone bet on ZO Skin Health, a brand you won’t find at Sephora. Now it could be worth $2 billion
- Japan has record 100,000 people aged over 100: How societies are ageing
- Pat Gelsinger and Naveen Rao: we’ve seen Silicon Valley move fast and break things, but consider the math of where we’re headed
- Harmony Biosciences CMO sells $1.65m in shares
- DR Congo rolls out Ebola vaccine for health workers as death toll rises
- Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study